Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02387710 · ClinicalTrials.gov registry record · Phase 2
Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02387710 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 18 participants.
The verdict
NCT02387710, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Interestingly, the severity of OSA is profoundly reduced in deep sleep (called "slow wave sleep"), potentially via an increase in the stimulus required to arouse from sleep. Here the investigators test the idea that the medication called "tiagabine" improves slow wave sleep and reduces OSA severity. The investigators will also test whether tiagabine raises the arousal threshold (more negative esophageal pressure), and whether detailed OSA "phenotyping" characteristics can predict the improvement in OSA severity with this intervention.
Interventions
- DRUG Placebo
- DRUG Tiagabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02387710
The ClinicalTrials.gov registry entry for NCT02387710 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02387710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02387710 about?
NCT02387710 is a clinical study titled "Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea". Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Interestingly, the severity of OSA is profoundly reduced in deep sleep (called "slow wave sleep"), potentially via an increase in the stimulus required to arouse from sleep. Here the investig...
What is the current status of trial NCT02387710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2015-03. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02387710?
The interventions under investigation include: Placebo (DRUG), Tiagabine (DRUG).
Who is sponsoring clinical trial NCT02387710?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.